comparemela.com

Adding perioperative tislelizumab to neoadjuvant chemotherapy and surgery can improve outcomes in patients with NSCLC, a phase 3 trial suggests. Adding perioperative tislelizumab to neoadjuvant chemotherapy and surgery can improve outcomes in patients with NSCLC, a phase 3 trial suggests.

Related Keywords

Tianjin ,China ,Dongsheng Yue ,Tianjin Medical University Cancer Institute , ,Safety Results ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.